Genmab — Februar 2020
-
Then, the use of daratumumab after a PD-1 or PDL-1 checkpoint blockers in solid tumors that's entirely up to Janssen. Janssen is following the field. They are looking at the Sanofi work with isatuximab and they have already said publicly that they are willing to move into solid tumors again with daratumumab, but then they will use SubQ daratumumab. And don't forget that we know of also this new HexaBody CD38 program, which will go into the clinic this year, which Genmab will drive, Asthika.
-
McJean: Den, der lever stille, lever godt :-)....og lad dig ikke snyde af Panikken
-
EL, ja, ØU er ikke altid lige heldige med deres timing
-
Bryan Garnier er meget positive:
While we have significantly increased our assumptions of OPEX for the years to come, we have also reviewed our scenario on Darzalex, and now targeting USD9.5bn at peak vs USD8.6bn, convinced by its ability to continue to grow significantly next year. -
Haha E L og Bulder. Enhver, som i Novods tilfælde, der arbejder med en model der konsekvent giver forkerte resultater i forhold til virkeligheden, må da på et eller andet tidspunkt overveje hvad der er galt med modellen. Når der er forskel mellem teori og virkelighed, bør man holde sig til virkeligheden. Det er bare et godt råd:-)
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind